Investigating the role of hair follicle stem cells in Hidradenitis Suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on understanding the mechanisms behind the chronic inflammatory condition known as Hidradenitis Suppurativa (HS) by examining hair follicle stem cells. Researchers will analyze skin biopsies and blood samples from patients diagnosed with HS to identify the pro-inflammatory characteristics of these cells. The study aims to uncover the genetic and cellular factors contributing to the disease's pathology, which could lead to better treatment options. By comparing the findings from HS patients to healthy individuals, the study seeks to elucidate the underlying causes of HS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients referred to the consultation of dermatology of Henri Mondor Hospital
* Diagnosis of Hidradenitis Suppurativa
* Age\> 18 y.o.
* Affiliation to a social security system

Exclusion Criteria:

* Patient under tutorship or curatorship
* Breastfeeding or pregnant women
* Refusal to sign the consent letter
* Patients benefiting from State Medical Aid

Where it's running

• Assistance Publique Hôpitaux de Paris - CHU Henri Mondor
  Créteil, Val-de-marne, France Recruiting

Study contacts

• Study coordinator: Claire HOTZ, MD
• Email: claire.hotz@aphp.fr
• Phone: 33-1-49-81-37-96

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Remibrutinib extension study for adults with moderate to severe hidradenitis suppurativa

  This extension study tests whether continuing remibrutinib is safe and helps skin symptoms in adults who completed prior HS trials.

  Recruiting at 61 sites Phase 3 Novartis · Birmingham, Alabama and 60 other locations · NCT07665437

• LAD328 in adults with hidradenitis suppurativa

  This study tests whether LAD328 works better than placebo for adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting Phase 2 Almirall, S.A. · Warsaw, Masovian Voivodeship · NCT07547813

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

• Secukinumab outcomes in Canadians with hidradenitis suppurativa

  It will see how well secukinumab works and how safe it is for adults in Canada with moderate-to-severe hidradenitis suppurativa who were newly prescribed it in routine care.

  Recruiting at 15 sites Novartis · Calgary, Alberta and 14 other locations · NCT07282015

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.